NCT05652192

SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC

Stereotactic Body Radiotherapy (SBRT) Combined With Chemotherapy and Tislelizumab in Metastatic Nasopharyngeal Carcinoma: A Single-arm, Phase Ⅱ Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing. This study preliminarily explored the efficacy and safety of SBRT combined with tislelizumab and chemotherapy in metastatic nasopharyngeal carcinoma. Hypofractionated radiotherapy combine with systemic chemotherapy and immunotherapy in advanced nasopharyngeal carcinoma. Not only it can achieve rapid response of distant metastases, but also to achieve long-term survival benefit for patients, which provides the reference for subsequent studies.

Conditions

• Advanced Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
RADIATION	SBRT	SBRT was added to systematic treatment (chemo+ PD-1 antibody)

Timeline

• Start date: 2022-09-15
• Primary completion: 2026-10-31
• Completion: 2026-12-31
• First posted: 2022-12-15
• Last updated: 2022-12-15

Locations

1 site across 1 country: China